Fred E Cohen
CIK 1339358 · last filed 2026-06-16
Fred E Cohen is a corporate insider who has filed 165 SEC Form 4 insider transactions across 12 companies since 2007. The most recent filing, for CDNA, was dated Jun 16, 2026. Across all open-market trades the lifetime net is −$3.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $48.7M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$48.70M
12
165
-$3.60M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CDNA | Director | 165,060 | $35.75 | $5.90M | $0 | 34 | 2026-06-16 |
| NTLA | Director | 216,653 | $10.89 | $2.36M | $1.40M | 12 | 2026-06-10 |
| KYTX | Director | 4,545,651 | $7.49 | $34.05M | $0 | 3 | 2026-05-29 |
| URGN | Director | 84,339 | $40.88 | $3.45M | $0 | 8 | 2024-08-08 |
| PGNY | Director | 22,693 | $30.76 | $698.0K | $0 | 6 | 2024-05-28 |
| VCYT | Director | 10,000 | $55.65 | $556.5K | -$1.07M | 9 | 2020-10-20 |
| GENOMIC HEALTH INC (GHDX) Delisted | Director | 75,188 | — | — | -$3.63M | 57 | 2019-10-03 |
| TNDM | Director | — | $17.76 | — | $0 | 7 | 2018-11-19 |
| BCRX | Director | 173,660 | $9.74 | $1.69M | -$294.0K | 19 | 2018-06-22 |
| Roka BioScience, Inc. (ROKA) Delisted | Director | — | — | — | $0 | 3 | 2017-06-30 |
| FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | Director | — | $178.75 | — | $0 | 2 | 2017-05-12 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Director | 24,807 | $38.00 | $942.7K | $0 | 3 | 2016-01-13 |
Recent Filings
165 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-16 | CDNA | Grant (A) | +9,795 | $0 | EDGAR |
| 2026-06-10 | NTLA | Grant (A) | +9,200 | $0 | EDGAR |
| 2026-05-29 | KYTX | Grant (A) | +5,093 | $0 | EDGAR |
| 2026-01-07 | NTLA | Buy (P) | +150,000 | $1.40M | EDGAR |
| 2025-06-17 | CDNA | Grant (A) | +12,103 | $0 | EDGAR |
| 2025-06-13 | NTLA | Grant (A) | +8,000 | $0 | EDGAR |
| 2025-06-03 | PGNY | Notice (144) | −62,244 | -$1.35M | EDGAR |
| 2025-06-02 | KYTX | Grant (A) | +16,634 | $0 | EDGAR |
| 2024-08-08 | URGN | Grant (A) | — | $0 | EDGAR |
| 2024-06-20 | CDNA | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.